IXC Invex Therapeutics Ltd
Healthcare · Biotechnology
· website
$0.11
52wk 0.09 – 0.15
Overall
39.6
Value
40.9
Growth
0.0
Health
100.0
Quality
0.0
Momentum
49.5
Dividend
—
Price
About Invex Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | 0.0% |
| 1 month | 0.0% |
| 3 months | 4.8% |
| 6 months | 19.6% |
| 1 year | -24.1% |
| 3 years | -45.0% |
Risk
| Volatility (1y ann.) | 91.9% |
| Beta vs ASX 200 | 0.11 |
| Sharpe (1y) | 0.10 |
| VaR 95% (1-day) | -9.1% |
| Max drawdown (1y) | -40.0% |
| Off 1-year high | -26.7% |
Technicals
| RSI(14) | 33 |
| vs 50DMA | -3.4% |
| vs 200DMA | -3.0% |
| Trend | Golden cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
40.9
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
—
Price / Book
82
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
49.5
6-month return vs ASX 200
79
Price vs 200-day average
40
Price vs 50-day average
33
Position in 52-week range
33
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$8.27M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
0.54
EV / EBITDA
—
Price / Book
2.12
ROE
-29.5%
Operating margin
-1,397.9%
Net margin
0.0%
Total cash
$4.02M
Total debt
$0
Current ratio
26.48
Debt / Equity
—
Free cash flow
$-957,658
Avg volume
22,487
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$951.22K
- Net income-$476.87K
- Diluted EPS-0.01
- Free cash flow-$652.57K
- Net debt-$5.38M